Arcus Biosciences Inc
NYSE:RCUS
Arcus Biosciences Inc
NYSE:RCUS
Price:
15.67 USD
-2.79%
Market Closed
Updated:
May 29, 2024
Arcus Biosciences Inc
Other Current Liabilities
|
Arcus Biosciences Inc
Other Current Liabilities Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Other Current Liabilities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Arcus Biosciences Inc
NYSE:RCUS
|
Other Current Liabilities
$124m
|
CAGR 3-Years
17%
|
CAGR 5-Years
71%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Current Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Current Liabilities
$3.3B
|
CAGR 3-Years
149%
|
CAGR 5-Years
406%
|
CAGR 10-Years
26%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Current Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Current Liabilities
$648.6m
|
CAGR 3-Years
32%
|
CAGR 5-Years
8%
|
CAGR 10-Years
27%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Current Liabilities
$516.7m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
23%
|
See Also
What is Arcus Biosciences Inc's Other Current Liabilities?
Other Current Liabilities
124m
USD
124m
USD
Based on the financial report for Mar 31, 2024, Arcus Biosciences Inc's Other Current Liabilities amounts to 124m USD.
What is Arcus Biosciences Inc's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 5Y
71%
71%
Over the last year, the Other Current Liabilities growth was 22%. The average annual Other Current Liabilities growth rates for Arcus Biosciences Inc have been 17% over the past three years , 71% over the past five years .
You don't have any saved screeners yet
